Acquirer(s)

  • Johnson & Johnson Inc

Target(s)

  • Pfizer Inc

Summary

Johnson & Johnson - proposed acquisition of Pfizer Inc's consumer healthcare business

Market definition

The proposed acquisition was considered in relation to the supply in Australia of:
1. worm treatments;
2. anti-diarrhoeals; and
2. nicotine replacement therapy products.

Competition analysis

The ACCC decided not to oppose the proposed acquisition subject to section 87B undertakings being provided by Johnson & Johnson and Pfizer Inc. The reasons for the ACCC's decision are set out in the Public Competition Assessment relating to this matter.

Statement of issues

Document title Date
Statement of Issues.

Public competition assessment

Document title Date
Public Competition Assessment.

Timeline

Date Event

ACCC received submission from Johnson & Johnson. ACCC commences review under the Merger Review Process Guidelines. Market inquiries commence.

ACCC requested further information from Johnson & Johnson. Indicative timeline suspended pending receipt of Johnson & Johnson's response.

ACCC received Johnson & Johnson's response to ACCC information request of 11 October.

Johnson & Johnson advised intention to make submission to ACCC addressing possible competition effects.

Closing date for submissions from interested parties.

ACCC received submission from Johnson & Johnson addressing possible competition effects.

Proposed date for announcement of ACCC's findings (30 November 2006) delayed pending the resolution of Applicant's claim for confidentiality and related matters.

Applicant's claim for confidentiality and related matters resolved. ACCC timeline recommenced.

ACCC published Statement of Issues outlining its preliminary competition concerns.

Closing date for submissions from interested parties responding to ACCC's Statement of Issues.

Johnson & Johnson submitted s.87B Undertaking relating to its divestiture proposal for market inquiries by ACCC, and ACCC commenced market inquiries on Johnson & Johnson's proposed divestiture.

Closing date for submissions from interested parties regarding Johnson & Johnson's proposed divestiture.

ACCC accepted section 87B undertakings from Johnson & Johnson and Pfizer and announced it will not oppose the proposed acquisition.